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Gamma aminobutyric acid (GABA)-mediated synapses and the oscillations they orchestrate are altered in autism. GABA-acting
benzodiazepines exert in some patients with autism paradoxical effects, raising the possibility that like in epilepsies, GABA
excites neurons because of elevated intracellular concentrations of chloride. Following a successful pilot study,
1 we have now
performed a double-blind clinical trial using the diuretic, chloride-importer antagonist bumetanide that reduces intracellular
chloride reinforcing GABAergic inhibition. Sixty children with autism or Asperger syndrome (3–11 years old) received for 3
months placebo or bumetanide (1mg daily), followed by 1-month wash out. Determination of the severity of autism was made
with video ﬁlms at day 0 (D0) and D90 by blind, independent evaluators. Bumetanide reduced signiﬁcantly the Childhood Autism
Rating Scale (CARS) (D90 D0; Po0.004 treated vs placebo), Clinical Global Impressions (Po0.017 treated vs placebo) and
Autism Diagnostic Observation Schedule values when the most severe cases (CARS values above the mean±s.d.; n¼9) were
removed (Wilcoxon test: P-value¼0.031; Student’s t-test: P-value¼0.017). Side effects were restricted to an occasional mild
hypokalaemia (3.0–3.5mMl
 1 K
þ) that was treated with supplemental potassium. In a companion study, chronic bumetanide
treatment signiﬁcantly improved accuracy infacialemotional labelling,and increased brain activation inareasinvolved in social
and emotional perception (Hadjikhani et al., submitted). Therefore, bumetanide is a promising novel therapeutic agent to treat
autism. Larger trials are warranted to better determine the population best suited for this treatment.
Translational Psychiatry (2012) 2, e202; doi:10.1038/tp.2012.124; published online 11 December 2012
Introduction
Autism is an early-onset pervasive developmental disorder
associated with social disability, communication impairments,
repetitive behaviours and restricted interests (ICD-10).
2,3,4–6
Genetic mutations that have an impact on synapse opera-
tion
7–13 and environmental factors during pregnancy and
delivery
14–17 contribute to autism.
GABAergic signals are altered in autism as evidenced by
the following:
(i) The excitation/inhibition ratio is modiﬁed in experimental
models;
12,17–21
(ii) Gamma—and other frequency—oscillations that are
instrumental in higher cognitive functions,
22–24 and gener-
ated by GABAergic neurons,
20,25–27 are reduced in
autism;
28–31
(iii) In some patients, Gamma aminobutyric acid (GABA)-
acting benzodiazepines increase anxiety
32 and decrease
catatonia when other treatments fail.
33–38 Other studies
using paired pulses of auditory evoked potentials or
transcranial magnetic stimuli
39,40 have, however, observed
no alterations of inhibition. Phenobarbital is less efﬁcient for
severe seizures,
41 aggravates paradoxically electroence-
phalogram discharges
42,43 and is associated with high
rates of complications,
44 suggesting that GABA may excite
neurons instead of inhibiting them in epilepsies. Elevated
levels of intracellular chloride ([Cl
 ]i) that shift the polarity
of the actions of GABA from inhibition to excitation are
observed in epileptic neurons and underlie the paradoxical
actions of phenobarbital.
45–50 These observations suggest
that reducing the intracellular concentration of chloride may
provide a useful treatment for autism.
Theintracellularlevelsofchlorideareprimarilycontrolledby
two chloride co-transporters—the chloride importer NKCC1
and the chloride exporter KCC2.
48,51,52 The diuretic bumeta-
nide is a high-afﬁnity-speciﬁc NKCC1 antagonist that reduces
[Cl
 ]i.
53 Bumetanide decreases the paradoxical actions of
phenobarbital in epilepsies
47,49,54,55 and is presently tested in
neonatal encephalopathic epilepsies in European and US
clinical trials (NCT01434225-NCT00830531). Bumetanide
has been used since 1975 in adults and since 1986 in children
to treat hypertension, broncho-pulmonary dysplasia, nephritic
syndromes or heart congestions, and its pharmacokinetic is
wellknown.
56Theuseofbumetanideissafe,providedthatitis
accompanied with clinical and biological surveillance in
children to check hypokalaemia.
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www.nature.com/tpFollowing an encouraging pilot open trial,
1 we performed a
double-blind randomised study using chronic administration
of bumetanide (3 months, 1mg daily) to children with autism/
Asperger (A/A). We show that the diuretic reduces signiﬁ-
cantly the severity of A/A with little side effects. In a parallel
study, bumetanide improved accuracy in facial emotional
labelling, and increased brain activation in areas involved in
social and emotional perception (Hadjikhani et al., submitted).
Our results pave the way for larger trials to develop this novel
therapeutic strategy.
Material and methods
In June 2009, following our successful pilot study on ﬁve A/A
children,
1 we obtained the authorisation from the ad hoc
committee of the Brest hospital to proceed with a double-blind
(60 children) randomised trial in A/A using bumetanide
(Committee of Persons Protections—west 6-570-6/4/2009).
The trial was approved by the French Health Products Safety
Agency (AFFSAPS-A90936-66, 4 December 2009), clinical
registration number NCT01078714. Written informed consent
was obtained from each parent or legal guardian. The study
was conducted in accordance with the provisions of the
declaration of Helsinki (1996) and Good Clinical Practice
guidelines.
Participants. Subjects were 3–11 years old children who
met the ICD-10 (World Health Organisation 92) criteria for
autistic disorders. This age range was selected as we receive
primarily that age in the Centre de Ressources Autisme, and
our wish to concentrate on this age to restrict the population
recruited. Diagnosis was conﬁrmed by ADI-R and Autism
Diagnostic Observation Schedule (Generic) (ADOS G)
57
revised in 1994,
5 also see Lord et al.,
6 with a diagnosis of
autism (F84,0) or Asperger syndrome (F84,5) and a Child-
hood Autism Rating Scale (CARS) X30. A child psychiatrist
(EL) with more than 10 years experience made the
diagnostic, reviewed medication histories before enrolment
and determined if the inclusion criteria were satisfactorily
met. We did not exclude any child from the assay relying
on the severity of the syndrome as we did not know on
which population the treatment would be beneﬁcial. All
patients had karyotypes and Fragile X tests. Patients were
excluded if they had karyotype abnormalities and/or
neurological antecedents (including epilepsies and febrile
seizures). Patients had no history of allergies to sulfona-
mides, hepatic, renal dysfunction or electrocardiogram
abnormalities. Other treatments—with the exception of
melatonin (1–4mg) for sleep disorders—were stopped at
least 3 weeks before entering the trial.
Treatment. The Centre of Clinical Investigation of Brest
specialised in designing clinical trials developed the design
and concept of the study. The direction of clinical research of
the hospital provided external supervisors to follow the
implementation of the trial. The hospital pharmacy made
undistinguishable tablets using pure bumetanide powder or
lactose that matched for smell, taste or viscosity. The
preparation of the active and placebo tablets was made in
accordance with European procedures.
As shown in Figure 1, the surveillance was performed once
a week after the onset of the treatment, then monthly until the
end of the treatment. It included checking orthostatic
hypotension, allergy, cramps, asthenia, diarrhoea, myalgia,
arthralgia, vertigo and nausea and conventional blood tests
(g-glutamyltransferase, transaminases, alkaline phospha-
tases, glycaemia, uric acid and creatine). A summary of the
conduction of the trial is shown in Figure 1.
Randomisation and blinding. The double-blind, rando-
mised, placebo-controlled trial of bumetanide was conducted
by the Centre de Ressources Autisme de Bretagne. Patients
were randomly assigned to receive either bumetanide or
placebo (0.5mg twice a day) fabricated by the pharmacy of
the hospital. The trial was conducted between June 2009 and
June 2010 and consisted in 3-month treatment (bumetanide
or placebo) followed for all patients (placebo and treated) by
a 1-month wash out. The evaluators (CD, MP, FJ, MG and
EL) were fully blind to the drugs as the labelling was
disclosed by the pharmacy only after the end of the 4-month
trial and wash-out periods. The data, collected in the written
questionnaires and video ﬁlms of the meetings with the
evaluators, were reported in case report forms to the data
management and coordinating centre, where they were
securely held and analysed. At the end of the 3-month
double-blind phase, all children were removed from treat-
ment during a 1-month wash-out period.
Figure 1 Schematic diagram of the protocol used. A total of 60 children were
recruitedforthetrial,6 withdrewfor variousreasons(see text)andtheremaining54
completed treatments and assessment. The video ﬁlm was not available for one
child and thus ADOS could not be performed. Tests included CARS at D0, 90 and
120 after 1-month wash out, CGI at D0, 90 and 120, and ADOS at D0 and 90.
Bumetanide and autism
E Lemonnier et al
2
Translational PsychiatryStudy assessment. The primary outcome was the CARS:
  The CARS is a behaviour-rating scale used to assess the
presence and severity of the symptoms of autism spectrum
disorder (ASD), and can be used to determine alterations
during time and efﬁcacy of treatments.
58–62 The notation was
obtained during a ﬁlmed session when the children were
placedinagameandanimateddiscussionwithcaregiver.The
ﬁlms were subsequently analysed (by CD, MP, FJ and MG) and
a discussion with the parents made to gain more information. In
one case, video was not available and, therefore, the CARS was
determined relying only on the parent interview, and ADOS
could not be made for this child (Figure 1). The CARS is
composed of 15 items and the notation is from 1 to 4 with
intermediary notes (1.5, 2.5 and so on). A score of X36 is
considered indicative of a severe autistic behaviour, and
between 30 and 36, a score indicate a mild–to-moderate autistic
disorder. The total score is calculated by adding the notes of the
15itemscomplementedbythenumberofitemswithascoreX3.
The secondary outcome were:
  The Clinical Global Impressions (CGI) rated by the
evaluating clinician to rate the severity of illness, change over
time and efﬁcacy of medication. CGI is used in the majority of
clinical trials to examine disease severity and has been used
withnovelgenerationpsychoticagents.
63Itiscomposedofan
estimation of the severity of ASD (at day 0), the CGI-
improvement scale and the CGI-efﬁcacy index (at D90).
  The ADOS G is a semi-structured, standardised assess-
ment of social interaction, communication, play and imagina-
tive use of materials for individuals suspected of having
ASDs.
5,6 The observational schedule consists of four mod-
ules, each administered to different individuals according to their
level of expressive language. Each sequence is of 20–40 min
and is video recorded. In keeping with earlier studies,
5,64,65 we
used the total score of all items and the individual subscales: A:
communication and language, B: reciprocal social interactions,
C: games, D: stereotyped behaviour and restricted interest and
E: other abnormal behaviours.
Statistical analysis. Improvement between D0 and D90
was deﬁned as the value at D0 minus the value at D90 for the
CARS. In addition, we compared D90 with D120 for CARS to
gain some information on the alterations during the wash-out
period. Improvements were compared between treated and
placebo groups using analysis of covariance with adjustment
for the initial value. Graphical tools and Shapiro–Wilk test
were used to assess residuals normality.
Improvements between D0 and D90 on the ADOS scales
and subscales were analysed by comparing CGI values at
D90betweentreatedandplacebogroupsusingWilcoxonrank
test. In addition, CARS and number of items 43 in the CARS
score were compared between D0 and D90 for each group,
using paired t-test. Statistical analyses were performed using
SAS version 9.1 and were based on the intention-to-treat
principle. All tests were two-sided and P-values o0.05 were
considered as signiﬁcant.
Results
Of the 103 children who were screened for the study, 43 did
not meet the criteria for enrolment, or the parents or children
declined participation. The remaining 60 children (details
in Supplementary Tables 1 and 2) were randomly
assigned to receive either bumetanide (1mg daily) or placebo
during 3 months followed by a wash-out period of 1 month
(Figure 1). Baseline characteristics of the patients
were similar in the bumetanide and placebo groups
(Supplementary Table 1). In all, 24 patients did not speak
(10 treated/14 placebo), 8 used a few words but no sentences
(5/3)and28spokecorrectly(15/13).Sixchildrendiscontinued
the trial shortly after the start, two patients (n¼1i n
each group) for enuresis (Supplementary Table 4), two
consequently to delayed consequences of a late arrest of
the drugs they were treated with (methylphenidate and
risperidone), one because of hypokalemia (3.1mMl
 1 K
þ
found at the end of trial to be on bumetanide) and one for
allergia/eczema(foundattheendofthetrialtobeonplacebo).
All other patients (54: found subsequently to be composed
of 27 treated and 27 placebo) completed the planned
programme (Figure 1).
The CARS test. The CARS revealed a statistically signiﬁ-
cant amelioration of total score (P¼0.004; Table 1). After 90
days of bumetanide, the treated groups shifted from severe
(CARS 436.5) to mild or medium severity (o 36.5). In
contrast, there was no signiﬁcant difference in the placebo
group between D0 and D90 (Table 1). The number of items
43 shifted from 9.6 to 6.2 in the bumetanide-treated group
and from 9.8 to 8.1 in the placebo group (P¼0.017). These
differences are also visible in the plots of the ensemble
values from all placebo and treated individuals (Figure 2, also
see Supplementary Table 6). Interestingly, although not
statistically signiﬁcant, there was a clear trend to return to
pretreatment values at the end of the 1-month wash-out
period (35.9±1.1–38.8 ±0.9 for bumetanide-treated and
39.3±0.9–40.5±0.7 for the placebo group).
The CGI test. A clinical amelioration with little side effects is
suggested by the therapeutic index of CGI (from 2.04 to 1.56,
P¼0.017) (Table 1). As shown in Table 2, we observed 33%
Table 1 CARS and CGI tests
Bumetanide Placebo Statistics
CARS D0 41.6±3.6 41.1± 4.1
CARS D90 36±5.7 39.3±4.9
Gain CARS D90 D0 5.6±4 1.8±5.1 P¼0.0044
Number of items 43 D0 9.6±2.2 9.8±2.5
Number of items 43, D90 6.2±3 8.1±2.9
Gain number of items D90–D0 3.4±2.5 1.7±3.3 P¼0.017
CARS D120 38.8±4.7 40.5±3.8
Loss CARS D90–D120 2.9±3.0 1.2±3.7
Number of items 43 D120 8.0±2.7 9.1±2.1
loss number of items 43 1.8±1.9 1.0±2.2
CGI (therapeutic index) 2.04±0.87 1.56±0.85 P¼0.017
Abbreviations: ASD, autism spectrum disorder; CARS, Childhood Autism
Rating Scale; CGI, Clinical Global Impressions.
Effects of bumetanide on ASD severity. Note the signiﬁcant reduction of the
severityofCARSafter 90days.Notealso the signiﬁcantamelioration oftheCGI
index. The values of CARS are indicated at D0, 90 and 120 (after 30-day wash
out). The gain in CARS numbers between D90 and D0 are noted, as well as the
number of items 43 at D0 and D90 and the differences between D90 and D0.
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77% with bumetanide.
The Autism Diagnostic Observation Schedule. We ﬁrst
used the ADOS test to determine the effects of the treatment
(26 patients—the movie was unavailable for one patient, see
Figure 1) versus placebo (27 patients). The total score and the
subscales (A–E) were pooled (total 41 notes varying from 0 to
3) and tested at t¼0 and 90. Gains in total and per category
scores were compiled for placebo and bumetanide-treated
patients. Average gains of ADOS total scores increased
moderately for treated (mean¼7.8, s.d.¼7.4) versus placebo
(mean¼5.3, s.d.¼6.6) patients (Figure 1). However, this
difference was not signiﬁcant using Wilcoxon test (P-
value¼0.178) and only 10% signiﬁcant using the unilateral
Student’s t-test (P-value¼0.099). We then subdivided the
analysis relying on the subscales (that is, A–E criteria). Of
these ﬁve subscales, only D (stereotyped behaviour and
restricted interest) was signiﬁcant (Wilcoxon test P-
value¼0.001). (Table 3, also see Supplementary Table 5).
Because of the heterogeneity of the population, we
reasoned that the treatment might differently have an impact
onpatientsaccordingtotheseverityofASDasdiagnosedwith
the CARS. Using the CARS values (ranking between 34 and
48.5 with a mean of 41.4), we segregated patients having the
highest or lowest CARS scores, that is, more or less than the
mean±s.d. (41.4 ± 3.9) corresponding to the most or least
severely affected children, respectively. In all, 9 out of 53
patients had CARS scores 445.2 (mean±s.d.: two bumeta-
nide and seven placebo), suggesting high severity. As shown
in Figure 3, bumetanide ameliorated total ADOS scores
signiﬁcantly of the 44 remaining patients (24 bumetanide/20
placebo; Wilcoxon: P-value¼0.031; Student’s t-test:
P-value¼0.017). In contrast (Figure 3), when the patients
with CARS scores o37.5 (mean±s.d.; three bumetanide and
six placebo) were segregated, the effects of treatment on
ADOS total scores of the 44 remaining patients (21 placebo
and 23 bumetanide) were not signiﬁcant (Figure 3; Wilcoxon:
P-value¼0.4; Student’s t-test: P-value¼0.26). These obser-
vations suggest that the treatment is more efﬁcient in less
severely affected children.
Safety and tolerability of the treatment. The only child that
was removed from the trial because of eczema was on
placebo (Supplementary Table 4). Two children were removed
from the trial on parental decision because of bed-wetting and
identiﬁed at the end of the trial to have been treated with
placebo (one) and bumetanide (one). Two children were
removed from the trial consequently to hyperactivity due to
withdrawal from their medication (methylphenidate and
risperidone); although that was stopped 3 weeks before the
trial (Figure 1). One child treated with bumetanide was
removed because of hypokalemia (n¼1) (Supplementary
Figure 2 All the values obtained with CARS are depicted. Note the signiﬁcant
differencesbetweenplaceboandbumetanidetreatedpatientsandapartialreturnto
pretreatment values after 1-month wash-out period. The number of items 43 was
also signiﬁcantly reduced as shown at the right side of the ﬁgure (number
corresponding toD0,D90andD120;***po0.005for D90and**po0.05forD120).
Table 2 Amelioration in CGI produced by bumetanide
Score CGI Bumetanide (n/%) Placebo (n/%)
2: signiﬁcant amelioration 14/51.8% 77.7% 6/22.2% 33.3%
3: small amelioration 7/25.9% 3/11.1%
4: no amelioration 6/22.2% 18/66.6%
Abbreviation: CGI, Clinical Global Impressions.
Note that 77.7% of children had a small or signiﬁcant amelioration with the
diuretic to be compared with only 33.3% in placebo. Conversely, 22.2% had no
amelioration with the diuretic and 66.6% in placebo.
Table 3 ADOS tests: differences between bumetanide and placebo
Gains in 90 days for various tested criteria
(Wilcoxon test)
P-
value
Signiﬁcance
level
Tests ADOS
Total (ABCDE) 0.1783
Total A 0.4085
Total B 0.7953
Total C 0.6453
Total D 0.002 o0.01
Total E 0.8904
Tests on ADOS total scores according to CARS
Total (ABCDE) for CARS oaverageþs.d. 0.0316 o0.05
Total A for CARS oaverageþs.d. 0.3727
Total B for CARS oaverageþs.d. 0.3741
Total C for CARS oaverageþs.d. 0.7837
Total D for CARS oaverageþs.d. 0.002 o0.01
Total E for CARS oaverageþs.d. 0.2864
Total (ABCDE) for CARS4average s.d. 0.4029
Total A for CARS 4average s.d. 0.8306
Total B for CARS 4average s.d. 0.9151
Total C for CARS 4average s.d. 0.3111
Total D for CARS 4average s.d. 0.0312
Total E for CARS 4average s.d. 0.3811
Abbreviations: ADOS, Autism Diagnostic Observation Schedule; CARS,
Childhood Autism Rating Scale.
Global ADOS values are not signiﬁcantly different (total P-value 0.1783).
Values per criteria are also not signiﬁcantly different except criterion D
(hyperactivity and restricted interest; 0.002). The ADOS values are then
compared after removing the most and least severe cases assessed relying on
CARS. When the most severe cases (nine) are removed (4meanþs.d.), the
difference treatment/placebo is signiﬁcant for the total value (P¼0.0316) and
for D criterion (P¼0.002). In contrast, the differences are not signiﬁcant when
the least severe cases are removed oaverage s.d.).
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þ were p3,5mMl
 1,w e
supplemented with potassium-gluconate syrup. This was
necessary in six of the bumetanide-treated children that had
a mild hypokalemia (3.5, 3.4, 3.1, 3.5, 3.5 and 3.4ml
 1).
Clinical and Biological surveillance revealed no alterations in
all the parameters that were checked (see Treatment). There
was no dehydration, as conﬁrmed by normal sodiums and
maintenance of weight (Supplementary Table 3). Therefore, in
keeping with the extensive use of bumetanide in babies and
children for several decades, the side effects in the present
trial were limited.
Qualitative illustrations. Two individual cases are detailed
below and depicted in the movies joined to this article (http://
vimeo.com/48520450; http://vimeo.com/48726291).
Case A (Al): a 6-year-old boy, with poor language capacity,
a high level of stereotyped behaviour, little social interaction,
hyperactivity and oppositional behaviour. No medication
before trial onset. He went for 5 half days a week to the
children hospital, two sessions of language therapy weekly
and public school to which he went 3 half days weekly with
caregiver. After 3 months of treatment, his parents, teachers
and caregivers at hospital and friends at school attested that
he participated signiﬁcantly better and in social games with
the psychologist (see movie). He also had an improved non-
verbal communication (eye contact and attention). The child
remained under treatment for over 18 months.
Case B (Cl): a 9-year-old boy, with good language capacity
(full spontaneous sentences), poor social exchange,
restricted social interactions, little eye-to-eye communication,
hyperactive and stereotyped behaviour. He goes to public
school with the help of a caregiver and has one weekly
session of re-education. No medication before trial onset.
After 3 months of treatment, there was a clear amelioration of
eye contact, communication exchange and social commu-
nication, reduction of hyperactivity and increased ‘presence’
with family and friends at school.
Several qualitative comments of the parents attest to its
positive effects, including a greater presence of the child,
facilitated visual communication and social exchanges. In
keeping with this, at the end of the wash-out period, almost all
the parents demanded to shift (continue) to bumetanide
treatment; 87 patients are presently treated with bumetanide,
some for 2 year. Supplemental potassium is provided to 30%
of them.
Discussion
These results conﬁrm and extend an earlier small open-label
pilotstudythattothebestofourknowledgewastheﬁrsttouse
bumetanide in autism. Our aims here were to test the adverse
effects of long-term treatment on child behaviour and the
therapeutic actions of bumetanide in A/A children indepen-
dently of developmental levels, leading to a rather hetero-
geneous population. Our ﬁnding should be interpreted in light
of these limitations and the lack of other tests like the Social
ResponsivenessScale,whichcouldhavebeenuseful.Inspite
of these limitations, bumetanide reduced the severity of the
symptoms, the parents used literally the same words to stress
that the children are more ‘present’ with enhanced commu-
nication with their environment. Using a similar treatment
paradigm, Hadjikhani et al. have recently found an ameliora-
tion of emotive face recognition in seven Asperger children
after treatment and activation after treatment of brain regions
involved in face recognition and emotion that were not
activated before (Hadjikhani et al., submitted). Therefore,
although the treatment does not ‘cure’ autism, the ameliora-
tion it produces is of sufﬁcient interest so as to invite larger
Figure3 Topﬁgure:BoxplotofADOStotalscoresgainsbetweenthebeginning
and the end of the trial (90 days later) for patient receiving placebo (left panel) and
treatment (right panel). Bottom: Boxplot of ADOS total scores gains but excluding
patients with ‘above normal’ CARS scores (that is, above mean±s.d.)—between
the beginning and the end of the trial (90 days later) for patient receiving placebo
(left panel) and treatment (right panel).
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unspeciﬁc pervasive developmental disorders.
The CARS has been extensively used as a screening
instrument to assess the changes in symptoms of autism
over time.
58,59 It is also used to assess the therapeutic
potentials of putative agents
61,62,66 and has been favourably
compared with tests of risperidone and aripiprazole in
the treatment of autism
60,67,68 (also see refs 68–70). Other
studies have used the same scales;
71–74 also, see the three
double-blind trials with aripiprazole versus placebo.
74–76
The CARS has also superior hit rate and less false-positive
identiﬁcations than ABC or other tests.
61,68,77–79 The thera-
peuticusefulnessandthebeneﬁt/riskratiowasalsoshownwith
the widely used CGI, revealing a signiﬁcant amelioration with
little side effects. Finally, with ADOS, there was a statistically
signiﬁcant amelioration when the most, but not the least,
severe cases (above mean±s.d.) were removed, suggesting
that the diuretic is less efﬁcient to treat severely affected
children with autism.
Direct evidence that bumetanide exerts its actions by
reducing intracellular chloride in central neurons in humans
is lacking. In epilepsies, bumetanide reduces the severity of
seizures in experimental animals in vivo and in vitro (see
above). The MECP2 genetic mutations involved in Rett
syndrome like embryonic valproate alter the expression of
the trophic factor BDNF that controls the intracellular chloride
levels, providing a link between ASD and intracellular
chloride.
47,80–86 In keeping with this, in vivo administration of
bumetanide to pups reduces GABA-generated network
activities, suggesting a central action of the diuretic
87 in spite
of its poor blood brain barrier permeability and relatively short
lifetime.
88 Also, we have recently found signiﬁcant reduction
of intracellular chloride levels in cortical neurons of two animal
models in slices Fragile X and in utero valproate (Tyzio et al.,
in preparation). Collectively, these observations are compa-
tible with a central action of bumetanide, although more
investigations in humans are required. Our long-lasting twice-
daily regimen adopted subsequently in our continuous open
trials may be helpful in that regard. Finally, only a small
hypokalaemia was observed in 30% of the children; this was
readily compensated with K
þ syrup. Therefore, in keeping
with an extensive use of bumetanide for decades, the use of
bumetanide inchronic conditions is safe with little side effects.
Summing up, our results suggest a promising a novel
therapeuticapproachtotreatASDchildren.Ourresultscallfor
larger multicentre trials with more restricted inclusion and
exclusion criteria and more extended investigations on the
dose/responseactionsofthediuretic.Aparticularlysigniﬁcant
improvement may be expected with an early diagnostic and
treatment initiation.
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